Status:
COMPLETED
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Relapsing Remitting Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: * To evaluate long term efficacy of alemtuzumab. * To evaluate the safety profile of participants who received ...
Detailed Description
The total duration per participants was up to 5.6 years. As per Study Investigator discretion, participants can be treated with additional courses of alemtuzumab or any commercialized DMTs. All part...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Participant had completed at least 48 months of the Extension Study CAMMS03409. Signed written informed consent form.
- Exclusion criteria:
- Participant participating in another investigational interventional study.
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
January 7 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 15 2020
Estimated Enrollment :
1062 Patients enrolled
Trial Details
Trial ID
NCT02255656
Start Date
January 7 2015
End Date
July 15 2020
Last Update
March 28 2022
Active Locations (131)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number 1086
Cullman, Alabama, United States, 00000
2
Investigational Site Number 1031
Phoenix, Arizona, United States, 85013
3
Investigational Site Number 1171
Phoenix, Arizona, United States, 85018
4
Investigational Site Number 1090
Tucson, Arizona, United States, 85704